Barclays analyst Etzer Darout raised the firm’s price target on Terns Pharmaceuticals (TERN) to $36 from $28 and keeps an Overweight rating on the shares. The company is converting to a patient based model for TERN-701 and the drug has the potential to take significant share of the chronic myeloid leukemia market, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Promising Outlook for TERN-701 in CML Market: Buy Rating Affirmed by Analyst
- Terns Pharmaceuticals price target raised to $35 from $28 at Truist
- Terns Pharmaceuticals price target raised to $30 from $22 at BMO Capital
- Terns Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating
- Terns Pharmaceuticals price target raised to $33 from $32 at Mizuho